Conventional tests had failed to detect his father’s prostate cancer—but his “liquid biopsy” technology did.
When Santa Cruz professor Richard Otte, 61, got an annual screening test for prostate cancer, called a PSA, the results came back negative. Shortly thereafter, he reached out to his son Gabriel, an entrepreneur and computational biologist, to let him know the good news.
